নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - fentanyl 16.8mg;   - transdermal patch - 100 mcg/h - active: fentanyl 16.8mg   excipient: durotak 87-4287 pegoterate   - the management of chronic cancer pain. the management of opioid-responsive chronic severe pain of non-malignant origin in opioid tolerant patients, after other conservative methods of analgesia have been tried. for use in accordance with nzma guidelines on chronic pain management and where there is no psychological contraindication, drug seeking behaviour or history of drug misuse.

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - fentanyl 2.1mg;   - transdermal patch - 12 mcg/h - active: fentanyl 2.1mg   excipient: durotak 87-4287 pegoterate   - the management of chronic cancer pain. the management of opioid-responsive chronic severe pain of non-malignant origin in opioid tolerant patients, after other conservative methods of analgesia have been tried. for use in accordance with nzma guidelines on chronic pain management and where there is no psychological contraindication, drug seeking behaviour or history of drug misuse.

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - fentanyl 4.2mg;   - transdermal patch - 25 mcg/h - active: fentanyl 4.2mg   excipient: durotak 87-4287 pegoterate   - the management of chronic cancer pain. the management of opioid-responsive chronic severe pain of non-malignant origin in opioid tolerant patients, after other conservative methods of analgesia have been tried. for use in accordance with nzma guidelines on chronic pain management and where there is no psychological contraindication, drug seeking behaviour or history of drug misuse.

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - fentanyl 6.3mg;   - transdermal patch - 37 mcg/h - active: fentanyl 6.3mg   excipient: durotak 87-4287 pegoterate   - the management of chronic cancer pain. the management of opioid-responsive chronic severe pain of non-malignant origin in opioid tolerant patients, after other conservative methods of analgesia have been tried. for use in accordance with nzma guidelines on chronic pain management and where there is no psychological contraindication, drug seeking behaviour or history of drug misuse.

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - fentanyl 8.4mg;   - transdermal patch - 50 mcg/h - active: fentanyl 8.4mg   excipient: durotak 87-4287 pegoterate   - the management of chronic cancer pain. the management of opioid-responsive chronic severe pain of non-malignant origin in opioid tolerant patients, after other conservative methods of analgesia have been tried. for use in accordance with nzma guidelines on chronic pain management and where there is no psychological contraindication, drug seeking behaviour or history of drug misuse.

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - fentanyl 12.6mg;   - transdermal patch - 75 mcg/h - active: fentanyl 12.6mg   excipient: durotak 87-4287 pegoterate   - the management of chronic cancer pain. the management of opioid-responsive chronic severe pain of non-malignant origin in opioid tolerant patients, after other conservative methods of analgesia have been tried. for use in accordance with nzma guidelines on chronic pain management and where there is no psychological contraindication, drug seeking behaviour or history of drug misuse.

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - testosterone 1.41%{relative} (12.2mg/system);   - transdermal patch - 12.2 mg - active: testosterone 1.41%{relative} (12.2mg/system)   excipient: ethanol glycerol glyceryl mono-oleate carbomer copolymer (type b) methyl laurate purified water sodium hydroxide - androderm® is indicated for testosterone replacement therapy for confirmed testosterone deficiency in males.

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - testosterone 24.3mg;   - transdermal patch - 24.3 mg - active: testosterone 24.3mg   excipient: ethanol glycerol glycerol mono-oleate carbomer copolymer type b methyl laurate purified water sodium hydroxide - androderm® is indicated for testosterone replacement therapy for confirmed testosterone deficiency in males.

কানাডা - ইংরেজি - Health Canada

sandoz canada incorporated - fentanyl - patch - 12mcg - fentanyl 12mcg - opiate agonists

কানাডা - ইংরেজি - Health Canada

sandoz canada incorporated - fentanyl - patch - 25mcg - fentanyl 25mcg - opiate agonists